Dr. Brian Druker Resigns as CEO of Knight Cancer Institute Amid Institutional Challenges

Dr. Brian Druker, CEO of the Knight Cancer Institute at OHSU, resigns amid concerns over the institution’s commitment to groundbreaking cancer research. His departure follows leadership turmoil at Oregon’s premier medical school, raising questions about the future of cancer treatment innovation. Dr. Druker, renowned for developing the life-saving drug Gleevec, emphasizes a return to laboratory work and patient care, signaling a critical transition for OHSU and the broader medical community.